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Thiamine tetrahydrofurfuryl 
disulfide promotes voluntary 
activity through dopaminergic 
activation in the medial  
prefrontal cortex
Masato Saiki1, Takashi Matsui1,2, Mariko Soya1,2, Tomomi Kashibe1, Takeru Shima1, 
Takeshi Shimizu3, Takehiro Naruto4, Takahito Kitayoshi4, Kouji Akimoto4, Shinji Ninomiya4 & 
Hideaki Soya  1,2
A physically active lifestyle is associated with better health in body and mind, and it is urgent that 
supporting agents for such lifestyles be developed. In rodents, voluntary locomotor activity as an active 
physical behavior may be mediated by dopaminergic neurons (DNs). Thiamine phosphate esters can 
stimulate DNs, and we thus hypothesized that thiamine tetrahydrofurfuryl disulfide (TTFD), a thiamine 
derivative, promotes locomotor activity via DNs in rats. Acute i.p. administration of TTFD enhanced 
rat locomotor activity in a normal cage. In vivo microdialysis revealed that TTFD-enhanced locomotor 
activity was synchronized with dopamine release in the medial prefrontal cortex (mPFC). Antagonism 
of the dopamine D1 receptor, but not D2 receptor, in the mPFC fully suppressed TTFD-enhanced 
locomotor activity. Finally, we found a TTFD dose-dependent increase in voluntary wheel running. Our 
findings demonstrate that DNs in the mPFC mediates TTFD-enhanced locomotor activity, suggesting 
the potential of TTFD to induce active physical behavior.
The higher the level of physical activity, the higher the levels of physical fitness. Higher levels of physical activity 
produce various physiological and psychological benefits1,2, while inactivity leads to a lack of vitality in the body 
and mind, making it a risk factor for lifestyle diseases, depression, and Alzheimer desease3–5. Globally, however, 
23% of adults and 81% of adolescents do not meet the WHO Global Recommendations on Physical Activity for 
Health6, and over 50% of employed adults and over 80% of over weight adults do not have leisure-time physical 
activity7,8. Thus, measures to enhance motivation for physical activity are required in modern human society.
Motivated behaviors, including locomotion, feeding, glucose seeking, and learning and memory, are regu-
lated by the dopaminergic neurons (DNs)9–13. The substantia nigra pars compacta (SNc) and ventral tegmental 
area (VTA) in the midbrain are the origin nucleus of DNs14, and, in particular, DNs from the VTA that project 
into the medial prefrontal cortex (mPFC) are involved in the reward system15. Amphetamine (AMPH) injection 
induces dose-dependent dopamine release in the mPFC and increases voluntary locomotor activity through the 
dopamine D1 receptor in rats16–18. These data suggest that DNs in the mPFC are a potential target of agents that 
induce motivation for physical activity.
Although we must be careful of addiction induced by drugs such as AMPH19, thiamine tetrahydrofurfuryl 
disulfide (TTFD), a popular thiamine derivative, is a potential agent for the activation of DNs without severe side 
effects. Thiamine deficiency causes the development of Wernicke’s encephalopathy20, hence thiamine plays an 
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important role in the central nervous system. TTFD is more rapidly absorbed than thiamine and it is metabolized 
into thiamine and its phosphorylated esters, which are thiamine monophosphate (TMP), thiamine diphosphate 
(TDP), and thiamine triphosphate (TTP)21,22. Chronic administration of TTFD ameliorates exercise-induced 
fatigue likely through the effect of TDP as a coenzyme of pyruvate dehydrogenase of skeletal muscles in humans 
and rats23,24. Further, the local injection of TTP and TDP into the rat striatum increases dopamine release25, sug-
gesting a possible role of TTFD on DNs in the brain. However, the effects of TTFD on the brain, particularly on 
the DNs in the mPFC, and voluntary locomotor activity remain unclear.
A recent study showed that benfotiamine (BFT), another thiamine derivative, decreases stress-induced anxiety 
behavior and GSK-3β activity in the PFC26. BFT also prevents stress-suppressed adult hippocampal neurogenesis 
in predator-stressed mice, independent of brain TDP levels27,28, suggesting the potential of thiamine derivatives as 
a psychopharmacological agents. TTFD has a similar bioavailability to BFT29, indicating the possibility for a role 
of TTFD in the brain. Therefore, we hypothesized that TTFD has important effects on the brain and contributes 
to the induction of physical activity via D1-receptor-mediated dopaminergic activity in the mPFC.
To test the present hypothesis, we employed a rat model of acute TTFD injection, voluntary locomotor activ-
ity detection with infrared radiation, and in vivo microdialysis. First, we investigated the effect of acute TTFD 
i.p. injection on voluntary activity in rats in a normal cage. Next, in vivo microdialysis revealed the dopamine 
dynamics in the mPFC with TTFD injection. Third, we examined the inhibitory effects of dopamine D1 and D2 
receptors on voluntary activity after TTFD injection. Finally, we assessed the effect of acute TTFD i.p. injection 
on voluntary running distance in a wheel cage.
Results
TTFD biphasically increases voluntary locomotor activity. Rats were given i.p. injection of TTFD 
(50 mg/kg) or saline, and their voluntary activity in a normal cage were monitored for 90 min. TTFD increased 
the total voluntary activity for the entire 90 min (P < 0.01, Fig. 1A), and we found a biphasic enhancement of 
TTFD-induced voluntary activity at 10 to 20 min and 50 to 90 min after administration (P < 0.01, Fig. 1B). These 
results are the first evidence for TTFD as a potential agent for inducing voluntary locomotor activity.
TTFD induces biphasic voluntary activity and dopamine release in the mPFC. Rats were given an 
i.p. injection of TTFD (50 mg/kg) or saline, and the extracellular dopamine and serotonin levels in their mPFC 
were measured using in vivo microdialysis for 120 min while monitoring voluntary activity in a normal cage 
(Fig. 2A). Consistent with the first experiment, TTFD increased overall voluntary activity during the 120 min 
monitored (P < 0.01, Fig. 2B), and a biphasic enhancement of TTFD-induced voluntary activity was observed at 
10 to 20 min and 60 to 80 min after administration (P < 0.01, Fig. 2C). Extracellular dopamine levels in the mPFC 
also increased biphasically at 20 to 40 min and 60 to 120 min after administration (P < 0.05, Fig. 2D). Serotonin 
levels remained basically unchanged but increased at 70 min after administration (P < 0.05, Fig. 2E). These results 
indicate the possibility that TTFD-enhanced voluntary activity is due to dopaminergic activation in the mPFC.
Antagonism of the dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppresses 
TTFD-induced voluntary activity. To examine whether TTFD induces voluntary activity through dopa-
minergic activation in the mPFC, we injected antagonists of the dopamine D1 and D2 receptors into the rat 
mPFC using microdialysis 30 min after TTFD administration. TTFD increased the total voluntary locomotor 
activity (P < 0.01), but the D1 receptor antagonist (SCH23390) fully inhibited the second peak of TTFD-induced 
voluntary activity (Fig. 3A). A D2 receptor antagonist (sulpiride) increased activity after injection (Fig. 3A,B), 
which is consistent with previous studies using D2-receptor antagonists30,31. In the present experiment, both 
antagonists increased dopamine and serotonin release in the mPFC (Fig. S1), indicating the validity of antago-
nist injection for central dopamine receptors32. We also injected SCH23390 into the mPFC 20 min before TTFD 
administration, and found that the antagonism of the D1 receptor fully inhibited both peaks of TTFD-induced 
Figure 1. TTFD biphasically increases voluntary locomotion. Data are expressed as mean ± standard error 
(n = 5–9/group). (A) Total voluntary activity in a normal cage. **P < 0.01 versus saline group (unpaired 
t-test). (B) Voluntary activity in a normal cage for 120 min. *P < 0.05; **P < 0.01 versus saline group (two-way 
ANOVA with Bonferroni’s post hoc tests).
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voluntary locomotor activity (P < 0.01, Fig. 4A,B). These results directly support the present hypothesis that 
TTFD contributes to the induction of voluntary locomotor activity via D1-receptor-mediated dopaminergic 
activity in the mPFC.
TTFD dose-dependent increases in voluntary running distance in running-wheel cage. Finally, 
we examined whether acute TTFD administration increases not only voluntary locomotor activity but also the 
amount of running exercise using a running-wheel cage. The i.p. administration of TTFD increased voluntary 
running distance in a dose-dependent manner (P < 0.05, Fig. 5A), particularly at 40 to 50 min after administra-
tion (P < 0.01, Fig. 5B). These results imply that TTFD enhances not only voluntary locomotor activity but also 
running exercise distance.
Discussion
This study tested the hypothesis that TTFD contributes to the induction of voluntary activity via 
D1-receptor-mediated dopaminergic activity in the mPFC. Our rat model of acute TTFD injection, voluntary 
activity detection with infrared radiation, and in vivo microdialysis showed that TTFD biphasically increases both 
voluntary activity and dopamine release in the mPFC (Figs 1 and 2). We also confirmed that antagonism of the 
dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppresses TTFD-induced voluntary activity 
(Figs 3 and 4). Furthermore, TTFD increased voluntary running distance in a dose-dependent manner in a wheel 
Figure 2. TTFD induces biphasic voluntary locomotion and dopamine release in the prelimbic cortex. Data are 
expressed as mean ± standard error (n = 11/group). (A) Schematic illustration and photomicrograph of brain 
section with Nissl staining. A guide cannula for microdialysis was implanted into the prelimbic area (PrL) of 
medial prefrontal cortex (mPFC). A scale bar represents 1,000 µm. (B) Total voluntary activity in a normal cage. 
**P < 0.01 versus saline group (unpaired t-test). (C) Voluntary activity in a normal cage for 120 min. (D) Extracellular 
dopamine levels. (E) Extracellular serotonin levels. *P < 0.05; **P < 0.01 versus saline group (two-way ANOVA with 
Bonferroni’s post hoc tests).
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cage (Fig. 5). These findings support the present hypothesis and provide evidence for a possible role of TTFD in 
inducing physical activity.
Here, we determined the dose of the TTFD injection (50 mg/kg) based on a previous study that exam-
ined how TTFD counters physical fatigue by improving energy metabolism during a swimming exercise23. 
Previous studies investigating the effects of BFT on the brain employed 200 mg/kg26,28, which is four-fold higher 
than the dose of TTFD in the present study. However, we observed that a dose of 50 mg/kg of TTFD induces 
D1-receptor-mediated dopaminergic activity in the mPFC as well as voluntary activity (Figs 1–4). We also 
confirmed that TTFD-induced voluntary running occurred with a dose of 50 mg/kg, but not with lower doses 
(Fig. 5). These data suggest the validity of our TTFD injection model and that 50 mg/kg is likely the lower dose 
limit for observable effects of thiamine derivatives on rat brains.
TTFD induced biphasic voluntary locomotor activity at 10 to 20 min and 50 to 90 min after administration, 
which was synchronized with dopaminergic activity via the D1 receptor, but not with serotonin release, in the 
mPFC (Figs 1–4). This periodicity is consistent with the timing of the REM-nonREM sleep cycle in rats, which 
is about 10 min (7–13 min)33. Here we performed experiments during the light period, when rats normally sleep. 
Further, dopamine, rather than serotonin, plays an important role in the maintenance of an awake state via the 
D1 receptor34,35. Therefore, a periodicity of at least two or more occurrences of TTFD-induced voluntary activity 
might be due to an awake state regulated by dopaminergic activity in the REM-nonREM sleep cycle. However, 
why first peak is sharp and second peak is long-lasting must be investigated in the further research.
Our in vivo microdialysis revealed TTFD-induced dopamine release in the mPFC (Fig. 2D). DNs from the 
VTA (A10) project into the mPFC14, indicating that TTFD might activate DNs from the VTA. However, how 
TTFD activates DNs is still unclear. A possible mechanism is the effect of TTFD-derived TDP, a coenzyme of 
pyruvate dehydrogenase. Acetyl-CoA synthesized from pyruvate by pyruvate dehydrogenase is an important neu-
ronal energy source derived from glucose or lactate, and can contribute to neuronal firing36. Furthermore, a pre-
vious study showed that local injection of TTP into the striatum increases dopamine release in the striatum, and 
that this was disrupted by an Na+ channel blocker (TTX), but not by a Ca2+ channel blocker (ω-CgTX)25. TTX 
can prevent the Na+ flux caused by TTP37. These previous studies indicate the possibility that TTFD increases 
dopamine release in the mPFC through energetic and signaling roles in enhancing Na+ permeability.
Furthermore, antagonism of the dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppressed 
the TTFD-induced voluntary locomotor activity (Figs 3 and 4). These results are consistent with previous studies 
showing that amphetamine increases dopamine release in the mPFC and locomotor activity of rats16,17, but that 
amphetamine-induced locomotor activity is inhibited by antagonism of the D1 receptor in the mPFC18. Also, we 
confirmed that antagonism of the D2 receptor induces a much higher level of locomotor activity (Fig. 3), which 
is consistent with previous studies showing hyper-behavior induced by D2-receptor antagonists through a disin-
hibiting effect30,31. Thus, we show the data with a D2-antagonist as a positive control, but this was excluded from 
statistical analyses because this was a planned comparison38. These findings support the present hypothesis that 
TTFD contributes to the induction of physical activity via D1-receptor-mediated dopaminergic activity in the 
mPFC, providing evidence for a possible role of TTFD in inducing physical activity.
We also observed that TTFD induces not only locomotor activity in rats in a normal cage (Figs 1–4), but 
also voluntary running in a dose-dependent manner in a running wheel cage at the timing following locomotor 
activation (Fig. 5). The degree of voluntary running behavior is regulated by DNs, likely via the D1 receptor 
in rodents31,39,40, suggesting a possible common neural mechanism in TTFD-induced locomotor activity and 
voluntary running. Although the linkage between TTFD-induced locomotor activity and wheel running is not 
fully investigated, TTFD-activated DNs together with locomotion could be a possible trigger for wheel running. 
Furthermore, chronic exercise, which is mimicked in rodents by voluntary running in a wheel cage41,42, produces 
various physiological and psychological benefits to prevent lifestyle diseases and to enhance brain functions in 
Figure 3. Dopamine D1 receptor antagonist, but not D2 receptor antagonist, inhibits TTFD-induced second 
peak of locomotor activation. Data are expressed as mean ± standard error (n = 5–6/group). (A) Total voluntary 
activity in a normal cage. *P < 0.05 versus saline + aCSF group, ##P < 0.01 versus TTFD + aCSF group (one-way 
ANOVA with Tukey’s post hoc tests). (B) Voluntary activity in a normal cage for 120 min. **P < 0.01 versus 
saline + aCSF group (two-way ANOVA with Bonferroni’s post hoc tests). The data from the TTFD + Sulpiride 
group are shown as a positive control and are excluded from statistical analysis by planned comparison.
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rodents and humans43–46. Although how TTFD-induced voluntary exercise affects physical and mental functions 
remains untested, TTFD may be a way to enhance active physical behavior with exercise and/or sport.
In general, motivation is the basis of animals’ behaviors such as food seeking, sexual behavior, and drug 
addiction relating with rewarding system47, which is regulated mainly by dopaminergic mechanisms48,49, and 
locomotion is a tool of it. However, previous studies showed that exercise itself activates dopamine metabolism 
in the brain (midbrain, striatum, hypothalamus, hippocampus etc.) likely for motor control and motivation in 
sustaining exercise, but it was returned to resting levels at fatigue50–53. Furthermore, dopaminergic mechanism 
could be involved in voluntary wheel running behavior in rodents31,40. These findings indicate the possibility for 
the presence of a motivation, intrinsic motivation, for exercise/locomotion itself. In the present study, TTFD 
increases locomotor activity via dopaminergic activation, independent of goals (Figs 1–4), suggesting a possible 
role for TTFD to promote motivation for locomotion and exercise.
TTFD is a popular agent for countering physical fatigue. Long-term administration of TTFD ameliorates the 
feeling of fatigue after exercise in trained participants24. Furthermore, six weeks of thiamine supplementation 
increases appetite, happiness, and decreases fatigue in elderly people with marginal thiamine deficiency54. These 
effects are likely exerted by TTFD/thiamine-derived TDP, a coenzyme of pyruvate dehydrogenase, which sup-
ports glucose metabolism in skeletal muscles23. In addition, in the current study, we observed for the first time 
that TTFD promotes dopamine release in the mPFC of normal healthy rats (Fig. 2D). Anti-depressant drugs, 
such as the dopamine reuptake inhibitor bupuropion, increase brain dopamine levels, producing psychological 
happiness in humans55 and preventing the onset of fatigue during prolonged exercise in rats56. Therefore, the 
anti-fatigue effect of TTFD could be induced not only by a metabolic effect, but also by dopaminergic activation 
in the brain.
Collectively, our findings provide direct evidence that TTFD administration induces voluntary locomotor 
activity via D1-receptor-mediated dopaminergic activity in the mPFC. TTFD also induces voluntary running in 
a dose-dependent manner, likely due to the same neural mechanism. This is the first study showing the effect of 
TTFD on the central nervous system. TTFD might help to promote physical activity, thereby improving physical 
and mental fitness.
Materials and Methods
Animals. Adult male Wister rats (SLC Inc., Shizuoka, Japan), housed and cared for in an animal facility, were 
fed a standard pellet diet (MF, Oriental Yeast Co., Ltd, Tokyo, Japan) and given water ad libitum. The room 
temperature was maintained at between 22 and 24 °C under a 12 h light/dark cycle (lights on: 07:00–19:00). All 
experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of 
Tsukuba, and all procedures and methods were performed in accordance with the relevant guidelines laid down 
by the animal ethics committee (Animal ethical approval number: 17-066). Every effort was made to minimize 
the number of animals used as well as any pain and discomfort.
Measurement of amount of voluntary activity. As per the method described by Lynch et al.57, the vol-
untary activity of rats was monitored in a cage (32 × 20 × 20 cm) using an Infrared Actimeter (Panlab, Barcelona, 
Spain). This device is equipped with three transparent cages, each with eight infrared lights located in a frame 
around the cage and connected to silent electronic counters. The apparatus is composed of a two-dimensional 
(horizontal and vertical axes) square frame, a frame support and a control unit. The lower tier records horizontal 
movements, while the upper tier records vertical movements. Samples were taken every 2 minutes. Raw data were 
computed with Actitrack® software (Panlab, Barcelona, Spain). Rats were fully acclimatized to the device for 
30 minutes per day for 1 week. On the day of the test, after confirming that the rats in the device cages had been 
sedentary for 20 minutes, an i.p. injection of TTFD or a vehicle (saline) was administered. After administration, 
Figure 4. Dopamine D1 receptor antagonist inhibits TTFD-induced first peak of locomotor activation. Data 
are expressed as mean ± standard error (n = 6/group). (A) Total voluntary activity in a normal cage. **P < 0.01 
versus TTFD + aCSF group (unpaired t-test). (B) Voluntary activity in a normal cage for 120 min. **P < 0.01 
versus TTFD + aCSF group (two-way ANOVA with Bonferroni’s tests).
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rats were placed back into the device cages and their movements were monitored. Each movement produced a 
signal caused by variation of inductance and capacity of the apparatus resonance circuit. These signals were auto-
matically converted into numbers and locomotion was counted by number of samples where the position of the 
subject is different from its position during the previous sample and different to the position of the 2nd sample 
back in time. This was separated from emotional activity without position movement. The activity of each rat was 
automatically recorded for 120 minutes after TTFD administration.
Surgery for microdialysis in the mPFC. The rats were anesthetized with isoflurane and placed in a stereo-
taxic instrument. An intracerebral guide cannula (outer diameter: 0.5 mm, AG-4, Eicom., Japan) was placed in the 
prelimbic area of the mPFC projected by DNs from VTA to regulate motivated behaviors58,59 (3.7 mm anterior to the 
bregma; 0.7 mm lateral; 3.0 mm below the pial surface)60. The cannula was secured to the skull with two anchoring 
screws and dental cement. To prevent occlusion, a dummy cannula (AD-4, Eicom., Japan) was inserted into the 
guide cannula. After the surgery, the animals were housed individually and were allowed to recover for at least week.
Microdialysis for dopamine detection in the mPFC. A microdialysis probe was inserted into the mPFC 
via the implanted guide cannula connected and perfused with Ringer’s solution (147 mM NaCl, 4 mM KCl, and 
2.3 mM CaCl2) at 2.0 μl/min so as to allow freely moving condition. A stable dialysate dopamine and serotonin 
concentration was usually obtained after a minimum of 2 h post-implantation of the probe. The 20 μl of microdi-
alysate was collected in every 10 minutes using a fraction collector (EFC-82; Eicom, Japan), and then automati-
cally injected into an HPLC-ECD system (HTEC-500; Eicom, Japan) by an autosampler (M-510; Eicom, Japan). 
Samples were analyzed for dopamine and serotonin concentration by the HPLC system with an EICOMPAK 
CAX column (2.0 mm,i.d. × 200 mm; Eicom, Japan) and a graft electrode (WE-3G; Eicom, Japan) set at 450 mV 
(vs Ag/AgCl reference electrode)61. The mobile phase contained 0.1 M ammonium acetate buffer, 0.05 mg/l 
sodium sulfate, 50 mg/l EDTA, and methanol (7:3, v/v), with a pH of 6.0. For data analysis, basal dopamine and 
serotonin concentration was estimated from an average of two HPLC time points before i.p. administration. At 
the end of each experiment, rats euthanized with pentobarbital, and the brain was removed. The position of the 
microdialysis probe was verified in coronal sections with Nissl staining.
Microdialysis for antagonism of dopamine receptors in the mPFC. The dosages of antagonists 
used in this study were selected based on a previous study2. Rats were infused with a D1 antagonist (SCH23390; 
10 mM) or a D2 antagonist (sulpiride; 10 mM) into the prelimbic area at a flow rate of 2 μl/min via the microdi-
alysis probe. S-(−)-sulpiride was dissolved in 0.1 N acetic acid, then neutralized with 0.1 M NaHCO3 (pH 7.2) 
and brought up to volume. Other antagonists were dissolved in artificial cerebral spinal fluid (aCSF, 145 mM 
NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.2 mM CaCl2, and 0.1 mM ascorbic acid). Before and during antagonism, we 
also collected dialysates, and these were analyzed for dopamine and serotonin concentrations using the HPLC 
system with a PP-ODS II column (4.6 × 30 mm; Eicom, Japan) and a graft electrode (WE-3G; Eicom, Japan) set 
at 400 mV (vs Ag/AgCl reference electrode). The mobile phase contained 0.1 M phosphate, 500 mg/l SDS, 50 mg/l 
EDTA and 2% v/v methanol, with a pH of 5.462.
Measurement of voluntary running distance. As per the method described by Lee et al.41, the voluntary 
running distance of rats was measured using a specially designed running-wheel apparatus (diameter = 31.8 cm, 
width = 10 cm; Rat Analyzer KI-103, Aptec, Kyoto, Japan). The resistance necessary to overcome the inertia of the 
wheel at its minimum load was 4.5 g. Distance is the number of revolutions times the circumference of the wheel. 
Rats were housed individually and had free access to the running-wheel apparatus for 1 week to be acclimatized. 
On the day of the experiment, the voluntary running distance of each rat was measured for 120 min.
Figure 5. TTFD increases voluntary running distance in running-wheel cage. Data are expressed as 
mean ± standard error (n = 4–5/group). (A) Total running distance in a running-wheel cage. *P < 0.05 versus 
TTFD 10 mg/kg group (one-way ANOVA with Tukey’s post hoc tests). (B) Running distance in a running wheel 
cage for 120 min. **P < 0.01 versus saline group (two-way ANOVA with Bonferroni’s post hoc tests).
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Statistical analysis. Data are expressed as mean ± standard error and analyzed using prism 5 (MDF Co., Ltd, 
Tokyo, Japan). Comparisons of the two groups were performed using Student’s t test for unpaired data. Group com-
parisons were performed using a one-way ANOVA, or two-way ANOVA with post hoc tests, including the planned 
comparisons38. Statistical significance was assumed at P < 0.05.
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